HC Wainwright Reaffirms Buy Rating for Addex Therapeutics (NASDAQ:ADXN)

HC Wainwright reaffirmed their buy rating on shares of Addex Therapeutics (NASDAQ:ADXN) in a research note published on Wednesday, Benzinga reports. The firm currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Addex Therapeutics’ FY2024 earnings at ($0.36) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.36) EPS.

Addex Therapeutics Stock Up 6.2 %

Shares of Addex Therapeutics stock opened at $10.86 on Wednesday. The business’s fifty day simple moving average is $8.21 and its 200-day simple moving average is $10.60. The firm has a market cap of $11.51 million, a PE ratio of -0.63 and a beta of 1.77. Addex Therapeutics has a 52 week low of $5.00 and a 52 week high of $27.90.

Addex Therapeutics (NASDAQ:ADXN) last posted its earnings results on Thursday, June 6th. The company reported ($1.37) EPS for the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. The company had revenue of $0.27 million during the quarter. As a group, equities analysts expect that Addex Therapeutics will post -11.8 earnings per share for the current year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.